OncoCyte Co. (NYSEAMERICAN:OCX) Receives $6.17 Average PT from Analysts
OncoCyte Co. (NYSEAMERICAN:OCX) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $6.17.
A number of research firms have recently issued reports on OCX. Zacks Investment Research downgraded OncoCyte from a “buy” rating to a “hold” rating in a research note on Saturday, February 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of OncoCyte in a report on Tuesday, March 23rd. Finally, Benchmark raised their target price on OncoCyte from $6.00 to $11.00 and gave the stock a “buy” rating in a report on Wednesday, March 17th.
In related news, CEO Ronald Asbury Andrews purchased 11,000 shares of the company’s stock in a transaction that occurred on Friday, March 19th. The stock was bought at an average price of $4.79 per share, for a total transaction of $52,690.00. Following the completion of the transaction, the chief executive officer now owns 113,698 shares in the company, valued at approximately $544,613.42. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.64% of the company’s stock.
Shares of NYSEAMERICAN:OCX opened at $4.72 on Friday. OncoCyte has a 52-week low of $1.15 and a 52-week high of $6.57. The firm has a market capitalization of $419.67 million, a P/E ratio of -9.08 and a beta of 2.23. The stock has a 50 day moving average price of $2.38 and a 200-day moving average price of $1.83. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.35 and a current ratio of 1.35.
OncoCyte (NYSEAMERICAN:OCX) last announced its earnings results on Monday, March 15th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.05 million. On average, equities analysts forecast that OncoCyte will post -0.46 EPS for the current fiscal year.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
Further Reading: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.